参考文献/References:
[1] Simonneau G,Montani D,Celermajer DS,et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J,2019,53(1).pii:1801913.
[2] Jing ZC,Xu XQ,Han ZY,et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension[J]. Chest,2007,132(2):373-379.
[3] Lau EMT,Giannoulatou E,Celermajer DS,et al. Epidemiology and treatment of pulmonary arterial hypertension[J]. Nat Rev Cardiol,2017,14(10):603-614.
[4] Kovacs G,Dumitrescu D,Barner A,et al. Definition,clinical classification and initial diagnosis of pulmonary hypertension:updated recommendations from the Cologne Consensus Conference 2018[J]. Int J Cardiol,2018,272S:11-19.
[5] Haberberger R,Schemann M,Sann H,et al. Innervation pattern of guinea pig pulmonary vasculature depends on vascular diameter[J]. J Appl Physiol (1985),1997,82(2):426-434.
[6] Zhang Y,Chen W,Xu Y,et al. Nerve distribution of canine pulmonary arteries and potential clinical implications[J].Am J Transl Res,2016,8(2):365-374.
[7] Zhou L,Zhang J,Jiang XM,et al. Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension induced by dehydrogenized monocrotaline[J]. JACC Cardiovasc Interv,2015,8(15):2013-2023.
[8] Zhang H,Zhang J,Chen MX,et al. Pulmonary artery denervation significantly increases 6-min walk distance for patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure:the PADN-5 study[J]. JACC Cardiovasc Interv,2019, 12(3):274-284.
[9] Bogaard HJ,Natarajan R,Mizuno S,et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats[J]. Am J Respir Crit Care Med,2010,182(5):652-660.
[10] Chen SL,Zhang FF,Xu J,et al. Pulmonary artery denervation to treat pulmonary arterial hypertension:the single-center,prospective,first-in-man PADN-1 study(first-in-man pulmonary artery denervation for treatment of pulmonary artery hypertension)[J]. J Am Coll Cardiol,2013,62(12):1092-1100.
[11] Linz D,Hohl M,Schutze J,et al. Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats:the role of renal sympathetic innervation[J]. Am J Hypertens,2015,28(2):256-265.
[12] Liu Q,Song JY,Lu D,et al. Effects of renal denervation on monocrotaline induced pulmonary remodeling[J]. Oncotarget,2017,8(29):46846-46855.
[13] Vaillancourt M,Chia P,Sarji S,et al. Autonomic nervous system involvement in pulmonary arterial hypertension[J]. Respir Res,2017,18(1):201.
[14] Verity MA,Bevan JA. Fine structural study of the terminal effecror plexus, neuromuscular and intermuscular relationships in the pulmonary artery[J]. J Anat,1968,103(Pt 1):49-63.
[15] Bristow MR,Ginsburg R,Umans V,et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure[J]. Circ Res,1986,59(3):297-309.
[16] Velez-Roa S,Ciarka A,Najem B,et al. Increased sympathetic nerve activity in pulmonary artery hypertension[J]. Circulation,2004,110(10):1308-1312.
[17] Chen SL,Zhang YJ,Zhou L,et al. Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo[J]. EuroIntervention,2013,9(2):269-276.
[18] Fujisawa T,Kataoka M,Kawakami T,et al. Pulmonary artery denervation by determining targeted ablation sites for treatment of pulmonary arterial hypertension[J]. Circ Cardiovasc Interv,2017,10(10).pii:e005812.
[19] Liu C,Jiang XM,Zhang J,et al. Pulmonary artery denervation improves pulmonary arterial hypertension induced right ventricular dysfunction by modulating the local renin-angiotensin-aldosterone system[J]. BMC Cardiovasc Disord,2016,16(1):192.
[20] Rothman AMK,Arnold ND,Chang W,et al. Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension[J]. Circ Cardiovasc Interv,2015,8(11):e002569.
[21] Zhang H,Zhang J,Xie DJ,et al. Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease[J]. Pulm Circ,2016,6(2):240-243.
[22] Esler MD,Bohm M,Sievert H,et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension:36 month results from the SYMPLICITY HTN-2 randomized clinical trial[J]. Eur Heart J,2014,35(26):1752-1759.
[23] Hoogerwaard AF,Adiyaman A,de Jong MR,et al. Changes in arterial pressure hemodynamics in response to renal nerve stimulation both before and after renal denervation[J]. Clin Res Cardiol,2018,107 (12),1131-1138.
[24] Krum H,Schlaich MP,Sobotka PA,et al. Percutaneous renal denervation in patients with treatment-resistant hypertension:final 3-year report of the Symplicity HTN-1 study[J]. Lancet,2014,383(9917):622-629.
[25] Li ZZ,Jiang H,Chen D,et al. Renal sympathetic denervation improves cardiac dysfunction in rats with chronic pressure overload[J]. Physiol Res,2015,64(5):653-662.
[26] Liang Z,Shi XM,Liu LF,et al. Renal denervation suppresses atrial fibrillation in a model of renal impairment[J]. PLoS One,2015,10(4):e0124123.
[27] Symplicity HTN-2 Investigators,Esler MD,Krum H,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[28] Zhao QY,Jiang XJ,Tang YH,et al. Beneficial effects of renal denervation on pulmonary vascular remodeling in experimental pulmonary artery hypertension[J]. Rev Esp Cardiol (Engl Ed),2015,68(7):562-570.
[29] Mahfoud F,Tunev S,Ewen S,et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation[J]. J Am Coll Cardiol,2015,66(16):1766-1775.
[30] da Silva Gon?alves Bos D, Happé C, Schalij I,et al. Renal denervation reduces pulmonary vascular remodeling and right ventricular diastolic stiffness in experimental pulmonary hypertension[J]. JACC Basic Transl Sci,2017,2(1):22-35.
[31] Huang Y,Liu YW,Pan HZ,et al. Transthoracic pulmonary artery denervation for pulmonary arterial hypertension[J]. Arterioscler Thromb Vasc Biol,2019,39(4):704-718.
[32] Fudim M,Sobotka AA,Yin YH,et al. Selective vs. global renal denervation: a case for less is more[J]. Curr Hypertens Rep,2018,20(5):37.
[33] Lu J,Wang Z,Zhou T,et al. Selective proximal renal denervation guided by autonomic responses evoked via high-frequency stimulation in a preclinical canine model[J]. Circ Cardiovasc Interv,2015,8(6).pii:e001847.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(5):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(5):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(5):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(5):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(5):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]